{"id":23143,"date":"2020-09-16T10:33:19","date_gmt":"2020-09-16T08:33:19","guid":{"rendered":"https:\/\/kymos.com\/news\/socios-globales-biofarmaceuticos\/"},"modified":"2020-09-16T10:33:19","modified_gmt":"2020-09-16T08:33:19","slug":"socios-globales-biofarmaceuticos","status":"publish","type":"post","link":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/","title":{"rendered":"Socios globales biofarmac\u00e9uticos"},"content":{"rendered":"<h3><span style=\"font-size: 14pt;\"><strong>Conozca a Pablo Cobo: l\u00edder de opini\u00f3n clave de KYMOS en el desarrollo de f\u00e1rmacos biol\u00f3gicos<\/strong><\/span><\/h3>\n<div class=\"blog-content\">\n<div class=\"field field-name-body field-type-text-with-summary field-label-hidden\">\n<div class=\"field-items\">\n<div class=\"field-item even\">\n<p><span style=\"font-size: 14pt;\">Nuestro responsable de Ensayos Biofarmac\u00e9uticos Pablo Cobo, licenciado en Qu\u00edmica y pionero en productos biol\u00f3gicos, recuerda sus inicios en Ipsen, cuando el desarrollo de productos pept\u00eddicos era muy diferente:<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>\u201cEn 1994, las empresas biofarmac\u00e9uticas realizaban la mayor parte de su trabajo de desarrollo internamente, pero debido a los altos costos del personal especializado y la instrumentaci\u00f3n, comenzaron a externalizar las actividades de prueba a organizaciones de investigaci\u00f3n externas\u201d, afirma el Sr. Cobo. \u201cHoy en d\u00eda, las empresas que carecen de la infraestructura necesaria pueden desarrollar productos biol\u00f3gicos y biosimilares espec\u00edficos de forma rentable gracias a las CRO y CDMO especializadas\u201d.   <\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Desaf\u00edos actuales en las pruebas de productos biofarmac\u00e9uticos  <\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">El departamento biofarmac\u00e9utico de KYMOS se centra en el control de calidad de productos biol\u00f3gicos innovadores y biosimilares, los dos principales segmentos biofarmac\u00e9uticos. Sin embargo, la demanda de estudios de comparabilidad de biosimilares ha aumentado significativamente en los \u00faltimos a\u00f1os. Pablo Cobo explica por qu\u00e9: <\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>Al igual que ocurri\u00f3 con los gen\u00e9ricos en la d\u00e9cada de los 80, muchos biofarmac\u00e9uticos de gran \u00e9xito est\u00e1n viendo expirar sus patentes y ahora tienen una gran demanda como biosimilares. Actualmente trabajamos con docenas de biosimilares y transferimos m\u00e9todos de clientes de todo el mundo: anticuerpos monoclonales (mAb) de Asia; hormonas recombinantes de Latinoam\u00e9rica; factores de crecimiento de Europa\u2026 Trabajar con biosimilares y sus productos biol\u00f3gicos de referencia es un desaf\u00edo, ya que son tan diversos como molecularmente complejos, y contar con los equipos necesarios para realizar todos los ensayos necesarios para su caracterizaci\u00f3n no siempre es la opci\u00f3n m\u00e1s eficiente. Como resultado, las empresas interesadas en entrar en el mercado de biosimilares tienden a externalizar los servicios de an\u00e1lisis con mayor frecuencia que antes las empresas de gen\u00e9ricos.  <\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Esta tendencia positiva es tan fuerte que, a pesar del brote de coronavirus, el equipo de Pablo ha experimentado un aumento de 2,5 veces en la demanda de servicios y un aumento del 44% en el valor promedio de las cotizaciones aprobadas en comparaci\u00f3n con el mismo per\u00edodo de 2019.<\/span><br \/>\n<span style=\"font-size: 14pt;\"><em>\u201cPrevemos que a medio plazo los biosimilares supondr\u00e1n el mayor porcentaje de la actividad de nuestro departamento\u201d,<\/em> concluye Cobo.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>\u00bfQu\u00e9 puede ofrecer el equipo de pruebas biofarmac\u00e9uticas de KYMOS que otras CRO no ofrecen?<\/strong><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Pablo Cobo est\u00e1 orgulloso de su equipo de expertos capacitados internamente y de sus instalaciones bien equipadas, pero hay otra raz\u00f3n importante por la que nuestros clientes eligen a KYMOS como su laboratorio de referencia:<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>\u201cMuchos de nuestros clientes provienen de pa\u00edses como China, Corea del Sur, Singapur, L\u00edbano, India o Argentina, donde existen alternativas de CRO y regulaciones favorables para las empresas\u201d,<\/em> comienza el Sr. Cobo. <em>\u201cSin embargo, todos los medicamentos fabricados fuera de la UE\/EEE, incluidos los biofarmac\u00e9uticos, deben ser analizados por un laboratorio certificado de la UE antes de su comercializaci\u00f3n. El hecho de que tambi\u00e9n seamos importadores y fabricantes certificados, capaces de ofrecer servicios de importaci\u00f3n, an\u00e1lisis de lotes y liberaci\u00f3n de lotes QP, facilita a estas empresas la transferencia de sus m\u00e9todos de fabricaci\u00f3n a KYMOS: podemos asistirles durante todo el proceso\u201d.<\/em> <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Uno de estos clientes globales es CELLTRION, empresa surcoreana l\u00edder especializada en mAb biosimilares y productos biol\u00f3gicos innovadores. Yong Suk Yang, director del equipo de operaciones de control de calidad global de CELLTRION, comparte su experiencia trabajando con KYMOS: <\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>\u201cActualmente estamos desarrollando m\u00faltiples proyectos nuevos de biosimilares m\u00e1s all\u00e1 de nuestro producto estrella Remsima (un biosimilar de infliximab vendido como Inflectra en EE. UU.) y consideramos a KYMOS una de las mejores CRO de Europa para la liberaci\u00f3n y prueba de f\u00e1rmacos\u201d.  <\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Pablo Cobo se suma a las palabras de Yang con su visi\u00f3n personal de proyectos anteriores:<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>CELLTRION es una empresa con m\u00e9todos anal\u00edticos robustos y un profundo conocimiento de su portafolio. Trabajar para ellos ha sido un verdadero privilegio, ya que nos ha brindado la oportunidad de implementar t\u00e9cnicas de caracterizaci\u00f3n de mAb de alto rendimiento, como la electroforesis capilar o el enfoque isoel\u00e9ctrico de imagen Protein Simple (iCE3).<\/em> El Sr. Cobo contin\u00faa: <em>\u00abConsidero los proyectos de nuestros clientes como una colaboraci\u00f3n rec\u00edproca: les ayudamos con todas sus necesidades de control de calidad y adquirimos valiosos conocimientos en el proceso. Tras muchos a\u00f1os probando productos biol\u00f3gicos y biosimilares innovadores, nuestra experiencia habla por s\u00ed sola\u00bb.<\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>Expectativas futuras<\/strong><\/span><br \/>\n<span style=\"font-size: 14pt;\">En 2012, el departamento de Pruebas Biofarmac\u00e9uticas de KYMOS constaba de tan solo dos personas. Hoy, tras una reubicaci\u00f3n y dos ampliaciones de laboratorio, el equipo de Pablo se ha multiplicado por diez y disfruta de un pron\u00f3stico de crecimiento optimista, impulsado por las tendencias actuales de externalizaci\u00f3n. Su trabajo constante y fiable ha recibido comentarios positivos de clientes de todo el mundo y ha situado a KYMOS entre los <strong><a href=\"https:\/\/www.packagingnews24.com\/biosimilar-testing-service-market-thriving-worldwide-with-top-key-playermerck-ppd-lab-holdings\/\" data-wpel-link=\"external\">10 principales proveedores mundiales de servicios de biosimilares<\/a><\/strong> . Con una posici\u00f3n tan envidiable, \u00bfqu\u00e9 m\u00e1s pod\u00eda pedir Pablo Cobo? Su respuesta es inmediata:    <\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>\u00a1Un nuevo laboratorio! El a\u00f1o pasado ampliamos nuestras instalaciones, \u00a1pero ya nos falta espacio!<\/em><\/span><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"font-size: 14pt;\">Aqu\u00ed puede ver m\u00e1s informaci\u00f3n sobre <a href=\"https:\/\/kymos.com\/es\/servicios\/analisis-y-control-de-calidad-de-cmc\/estudios-de-comparabilidad-de-biosimilares\/\" data-wpel-link=\"internal\"><strong>las pruebas de biosimilares<\/strong><\/a> <a href=\"mailto:info@kymos.com\" data-wpel-link=\"internal\">de<\/a> KYMOS <strong>, <a href=\"https:\/\/kymos.com\/es\/servicios\/analisis-y-control-de-calidad-de-cmc\/control-de-calidad-de-productos-biologicos-y-biosimilares\/\" data-wpel-link=\"internal\">la caracterizaci\u00f3n de productos biol\u00f3gicos y biosimilares<\/a><\/strong> y <a href=\"https:\/\/kymos.com\/es\/servicios\/servicios-preclinicos-y-clinicos\/bioanalisis-e-inmunogenicidad-de-productos-biologicos-y-biosimilares\/\" data-wpel-link=\"internal\"><strong>el bioan\u00e1lisis de productos biol\u00f3gicos y biosimilares<\/strong><\/a> o contactarnos en <a href=\"mailto:comercial@kymos.com?subject=Nuevos%20instrumentos%20en%20Kymos\" data-wpel-link=\"internal\">commercial@kymos.com<\/a> .<\/span><\/p>\n<p><span style=\"font-size: 14pt;\">CELLTRION es una empresa l\u00edder en la industria farmac\u00e9utica coreana. Lanzaron el primer \u00abbiosimilar de anticuerpos\u00bb del mundo en un pa\u00eds con un sector farmac\u00e9utico relativamente subdesarrollado y planean crecer como una compa\u00f1\u00eda biofarmac\u00e9utica global con enfoques \u00fanicos en productos farmac\u00e9uticos de mol\u00e9culas peque\u00f1as y nuevos negocios como la plataforma de atenci\u00f3n m\u00e9dica ubicua. Para m\u00e1s informaci\u00f3n sobre CELLTRION, cont\u00e1ctenlos en <a href=\"mailto:contact@celltrion.com\" data-wpel-link=\"internal\">contact@celltrion.com<\/a> .  <\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Conozca a Pablo Cobo: l\u00edder de opini\u00f3n clave de KYMOS  [&#8230;]<\/p>\n","protected":false},"author":6,"featured_media":21662,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[184],"tags":[],"class_list":["post-23143","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-grupo-kymos"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Socios globales biofarmac\u00e9uticos | Kymos<\/title>\n<meta name=\"description\" content=\"Pablo Cobo, Responsable de Pruebas Biofarmac\u00e9uticas de CELLTRION comparte su visi\u00f3n sobre el mercado biofarmac\u00e9utico\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Socios globales biofarmac\u00e9uticos | Kymos\" \/>\n<meta property=\"og:description\" content=\"Pablo Cobo, Responsable de Pruebas Biofarmac\u00e9uticas de CELLTRION comparte su visi\u00f3n sobre el mercado biofarmac\u00e9utico\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-16T08:33:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"437\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"Socios globales biofarmac\u00e9uticos\",\"datePublished\":\"2020-09-16T08:33:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/\"},\"wordCount\":1015,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"articleSection\":[\"Kymos Group\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/\",\"name\":\"Socios globales biofarmac\u00e9uticos | Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"datePublished\":\"2020-09-16T08:33:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Pablo Cobo, Responsable de Pruebas Biofarmac\u00e9uticas de CELLTRION comparte su visi\u00f3n sobre el mercado biofarmac\u00e9utico\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png\",\"width\":800,\"height\":437,\"caption\":\"Biopharmaceutical Global Partners\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/socios-globales-biofarmaceuticos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Socios globales biofarmac\u00e9uticos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/es\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/es\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/es\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Socios globales biofarmac\u00e9uticos | Kymos","description":"Pablo Cobo, Responsable de Pruebas Biofarmac\u00e9uticas de CELLTRION comparte su visi\u00f3n sobre el mercado biofarmac\u00e9utico","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/","og_locale":"es_ES","og_type":"article","og_title":"Socios globales biofarmac\u00e9uticos | Kymos","og_description":"Pablo Cobo, Responsable de Pruebas Biofarmac\u00e9uticas de CELLTRION comparte su visi\u00f3n sobre el mercado biofarmac\u00e9utico","og_url":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/","og_site_name":"Kymos","article_published_time":"2020-09-16T08:33:19+00:00","og_image":[{"width":800,"height":437,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"Escrito por":"Joan Puig de Dou","Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/es\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"Socios globales biofarmac\u00e9uticos","datePublished":"2020-09-16T08:33:19+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/"},"wordCount":1015,"image":{"@id":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","articleSection":["Kymos Group"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/","url":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/","name":"Socios globales biofarmac\u00e9uticos | Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","datePublished":"2020-09-16T08:33:19+00:00","author":{"@id":"https:\/\/kymos.com\/es\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Pablo Cobo, Responsable de Pruebas Biofarmac\u00e9uticas de CELLTRION comparte su visi\u00f3n sobre el mercado biofarmac\u00e9utico","breadcrumb":{"@id":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/Biopharmaceutical-Global-Partners_srt-e1658232466300.png","width":800,"height":437,"caption":"Biopharmaceutical Global Partners"},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/es\/news\/socios-globales-biofarmaceuticos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/es\/"},{"@type":"ListItem","position":2,"name":"Socios globales biofarmac\u00e9uticos"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/es\/#website","url":"https:\/\/kymos.com\/es\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/kymos.com\/es\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/es\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/posts\/23143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/comments?post=23143"}],"version-history":[{"count":0,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/posts\/23143\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/media\/21662"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/media?parent=23143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/categories?post=23143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/es\/wp-json\/wp\/v2\/tags?post=23143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}